Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERISCOPE-2
2023-510159-53-01Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial of docetaxel and oxaliplatin in gastric adenocarcinoma and peritoneal carcinomatosis (PC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
docetaxeloxaliplatin
03
Conditions
gastric adenocarcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2023-510159-53-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510159-53-01.